Business
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Organizational restructuring and operating cost reduction ahead of plan Focus on operational excellence, revenue growth, and improving Adjusted EBITDA SAN
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":"\nOrganizational restructuring and operating cost reduction ahead of plan\n\n\nFocus on operational excellence, revenue growth, and improving Adjusted EBITDA\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nMaravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates.\n\n\nKey Financial Results:\n\n\n\nQuarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;\n\n\n\nAnnual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of $(31.2) million; and\n\n\n\nIntroduced full year 2026 revenue guidance range of $200 million to $210 million and full year 2026 Adjusted EBITDA guidance range of $18 million to $20 million.\n\n\n\n“Driven by strong execution across the organization, we exceeded our revenue expectations and returned to positive Adjusted EBITDA in the fourth quarter, underscoring the operating leverage of our new model,\" said Bernd Brust, CEO, Maravai LifeSciences.\n\n\nBrust continued, “We enter 2026 well positioned to drive operational excellence, accelerate revenue growth, and continue improving Adjusted EBITDA as we work toward creating long-term value for all stakeholders.\"\n\n\nFinancial Guidance for Full Year 2026\n\n\nMaravai’s financial guidance for the full year 2026 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below.\n\n\nRevenue for the full year 2026 is expected to be in the range of $200 million to $210 million.\n\n\nAdjusted EBITDA (non-GAAP) is expected to be in the range of $18 million to $20 million.\n\n\nAs it relates to forward-looking Adjusted EBITDA, Maravai cannot provide guidance for the most directly comparable GAAP measure or a reconciliation of this non-GAAP financial measure because it is unable to provide a meaningful or accurate calculation or estimation of certain significant reconciling items without unreason...